SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LuckyIrishMan who wrote (1898)4/13/1999 9:20:00 PM
From: John Starks  Read Replies (1) of 2135
 
I saw Folkman speak today in New York. Lots of old stuff reported but some things I think were new (new to me, anyway) and figured I would share it with the thread, for what its worth. First of all, after extensive protocol comparison, he is sure that the reason NCI had so much trouble reproducing the results with endostatin is because they were not supplementing their culture media with zinc when generating the recombinant protein (endostatin has a low-affinity zinc binding site essential for its function). Second, they see a great effect (in mice still) on tumor shrinkage with low doses of endostatin when combined with moderate radiation therapy (64% shrinkage compared with 12% with this level of endo alone and 17% with radiation alone. Third, they have a paper submitted to Nature which "strongly suggests" that anti-angiogenesis agents are not limited to the treatment of solid tumors but are also effective for at least 3 types of leukemias. He did not elaborate at all on this last bit and it mystifies me.
When it comes out though, count on heavy press coverage.

And he used the same joke about the angry colleagues who couldn't reproduce his results calling him collect to complain. I guess when you come up with the cure for cancer you are allowed to reuse old material.

--John
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News